The 50-day moving average for RCUS moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 75 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for RCUS entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 215 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.016) is normal, around the industry mean (3.596). P/E Ratio (-4.640) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. RCUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The 10-day RSI Oscillator for XNCR moved out of overbought territory on November 13, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In 22 of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XNCR as a result. In 65 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for XNCR turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 40 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
XNCR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 190 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 143 of 197 cases where XNCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.282) is normal, around the industry mean (3.596). P/E Ratio (-16.551) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RCUS | XNCR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 84 | 34 | |
P/E GROWTH RATING 1..100 | 14 | 97 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XNCR's Valuation (16) in the Biotechnology industry is somewhat better than the same rating for RCUS (60) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew somewhat faster than RCUS’s over the last 12 months.
XNCR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to RCUS’s over the last 12 months.
XNCR's SMR Rating (97) in the Biotechnology industry is in the same range as RCUS (98) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew similarly to RCUS’s over the last 12 months.
XNCR's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for RCUS (84) in the Pharmaceuticals Major industry. This means that XNCR’s stock grew somewhat faster than RCUS’s over the last 12 months.
RCUS's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for XNCR (97) in the Biotechnology industry. This means that RCUS’s stock grew significantly faster than XNCR’s over the last 12 months.
| RCUS | XNCR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 88% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 65% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 82% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 73% |
| Advances ODDS (%) | 12 days ago 77% | 10 days ago 75% |
| Declines ODDS (%) | 3 days ago 80% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 73% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RCUS’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RCUS’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).
RCUS (@Biotechnology) experienced а -11.20% price change this week, while XNCR (@Biotechnology) price change was -10.81% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.90%. For the same industry, the average monthly price growth was -16.46%, and the average quarterly price growth was -27.70%.
RCUS is expected to report earnings on Mar 02, 2027.
XNCR is expected to report earnings on Feb 24, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To RCUS | 1D Price Change % | ||
|---|---|---|---|---|
| RCUS | 100% | -1.01% | ||
| VIR - RCUS | 50% Loosely correlated | -5.41% | ||
| DYN - RCUS | 47% Loosely correlated | -3.31% | ||
| KURA - RCUS | 46% Loosely correlated | -5.99% | ||
| RCKT - RCUS | 44% Loosely correlated | -7.58% | ||
| IDYA - RCUS | 43% Loosely correlated | -2.33% | ||
More | ||||
A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To XNCR | 1D Price Change % | ||
|---|---|---|---|---|
| XNCR | 100% | -2.21% | ||
| VCYT - XNCR | 52% Loosely correlated | +0.36% | ||
| DYN - XNCR | 52% Loosely correlated | -3.31% | ||
| ORKA - XNCR | 49% Loosely correlated | -1.80% | ||
| VIR - XNCR | 49% Loosely correlated | -5.41% | ||
| RCUS - XNCR | 48% Loosely correlated | -1.01% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BWOW | 13.42 | N/A | N/A |
| Bitwise Dogecoin ETF (BWOW) | |||
| MFLX | 16.32 | -0.06 | -0.34% |
| First Trust Flexible Municipal High Income ETF (MFLX) | |||
| VEXC | 80.51 | -3.95 | -4.68% |
| Vanguard Emerging Markets Ex-China ETF (VEXC) | |||
| XOVR | 17.76 | -1.27 | -6.67% |
| ERShares Private-Public Crossover ETF (XOVR) | |||
| ETHV | 23.35 | -2.32 | -9.04% |
| VanEck Ethereum ETF (ETHV) | |||